Safety Evaluation of FMD Vaccine in Mice

The safety of the FMD vaccine containing D-galacto-D-mannan was evaluated in mice as previously described (29 (link)). The vaccine compositions for the usual vaccination in mice were as follows: purified antigens obtained via antigen purification from FMDV type O (O PA2) and type A (A YC) (0.375 μg + 0.375 μg/dose), ISA 206 (Seppic, Paris, France; 50% w/w), 10% aluminum hydroxide [Al(OH)₃], and 15 μg/mouse Quil-A (InvivoGen, CA, USA), with the addition of 100 μg of D-galacto-D-mannan/dose/mouse in a total volume of 100 μL. Mice were administered with a vaccine equivalent to fivefold (500 μL) the volume of the usual vaccination dose (100 μL). All mice (n = 5/group) were vaccinated with IP injection into the peritoneum (0 dpi). To evaluate the safety of the vaccines, survival rates and body weight changes were evaluated up to 7 dpi.